Atopic dermatitis

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

Retrieved on: 
Friday, February 16, 2024
Ministry, Histamine, Sinusitis, Omalizumab, Quality of life, Atopic dermatitis, Prurigo nodularis, MHLW, Asthma, Cell, Safety, Patient, CSU, Disease, Polyp (medicine), Pharmaceutical industry

Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs.

Key Points: 
  • Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs.
  • CSU is a chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and persistent itch.
  • CSU is typically treated with histamine (H1) antihistamines, medicines that target H1 receptors on cells to control symptoms of urticaria.
  • In addition to CSU, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and prurigo nodularis.

ElleVet Academy Launches with Classes on Cannabinoid Veterinary Science, Offering Free RACE Approved CE Credits for Veterinary Professionals

Retrieved on: 
Thursday, February 15, 2024
CE, Anxiety, Research, Education, Atopic dermatitis, Dog, Parent, Cannabinoid, Curriculum, Entrepreneurship, Veterinary medicine, Pharmacokinetics, Cat, Patient, CBD, Knowledge, Osteoarthritis, Epilepsy, Science

PORTLAND, Maine, Feb. 15, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences, the leading authority on cannabinoid veterinary science, proudly announces the launch of ElleVet Academy (ellevetacademy.com), its online learning platform offering free continuing education (CE) credits to veterinary professionals. ElleVet Academy courses aim to empower veterinary professionals with the knowledge and skills needed to confidently incorporate cannabinoid-based products into their practice to support patients with osteoarthritis, epilepsy, atopic dermatitis, and anxiety.

Key Points: 
  • PORTLAND, Maine, Feb. 15, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences, the leading authority on cannabinoid veterinary science, proudly announces the launch of ElleVet Academy ( ellevetacademy.com ), its online learning platform offering free continuing education (CE) credits to veterinary professionals.
  • "ElleVet Academy represents a pivotal step in advancing veterinary education," said Dr. Joseph J. Wakshlag, Chief Veterinary Medical Officer, ElleVet Sciences.
  • Free Continuing Education Credits: Veterinary professionals can earn RACE-approved CE credits at no cost, making ElleVet Academy the most accessible and comprehensive resource for gaining essential education in cannabinoid veterinary science.
  • Scientific Expertise: ElleVet Academy courses were designed by the same veterinary professionals and researchers who brought cannabinoid veterinary science to the forefront of pet care.

Non-Lesional Filaggrin Expression is Predictive of Asthma Development in Children with Atopic Dermatitis

Retrieved on: 
Wednesday, February 14, 2024
AAAAI, Research, Multimedia, TEWL, Atopic dermatitis, Parent, Skin, Risk, Mechanism, FLG, PFT, Patient, Journal, Diagnosis, Wheeze, Ageing, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Filaggrin (FLG) expression in non-lesional skin and observations of the skin barrier can lead to early diagnosis for children with asthma according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting, in Washington, DC, this month.

Key Points: 
  • Low Filaggrin expression in children aged 2 to 3 years old is a significant predictor of school-age asthma.
  • Specifically, filaggrin expression in the normal appearing skin predicts asthma development and is a better predictor than parent-report of physician-diagnosed asthma" says primary author Wan Chi Chang, MS.
  • In the study, pulmonary function testing (PFT) was conducted in 96 children, aged 7 to 8 years old, with atopic dermatitis from the Mechanisms of Progression from Atopic Dermatitis to Asthma in Children cohort.
  • Logistic regression evaluated the predictability of physician-diagnosed asthma reported by parents, transepidermal water loss (TEWL), SCORing Atopic Dermatitis (SCORAD) and skin expression of FLG for asthma.

Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Retrieved on: 
Wednesday, February 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Therapy, Atopic dermatitis, Psoriasis, Caregiver, Food, Shanda, Sleep, Patient, Dermatitis, Itch, Skin, Pharmaceutical industry

VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.

Key Points: 
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.
  • VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.
  • On May 24, 2022, Dermavant announced the FDA approved VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Retrieved on: 
Wednesday, February 14, 2024
Lifestyle, Biotechnology, FDA, Health, Pharmaceutical, Cosmetics, Research, Retail, Consumer, Science, Clinical Trials, Nemolizumab, Quality of life, Atopic dermatitis, Food, Prurigo nodularis, File, Safety, Prurigo, European Medicines Agency, Sleep, Patient, Diagnosis, Breakthrough therapy, Itch, Priority review

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023.

Key Points: 
  • This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023.
  • Priority Review is granted for medicines that would significantly improve the treatment, diagnosis or prevention of serious conditions.
  • The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.
  • “The relentless itch experienced by many people living with prurigo nodularis and atopic dermatitis has a significant impact on their overall quality of life.

Home Reintroduction of FPIES Food Triggers May Be Safe and Effective for Children

Retrieved on: 
Tuesday, February 13, 2024
AAAAI, FPIES, Research, Multimedia, Eosinophilic esophagitis, Quality of life, Atopic dermatitis, Immunoglobulin E, Asthma, Drug, Communication, Annual general meeting, NYU, Rhinitis, Milk, Patient, Journal, Food, American Academy

MILWAUKEE, Feb. 13, 2024 /PRNewswire-PRWeb/ -- Home reintroduction of pediatric food protein-Induced enterocolitis syndrome (FPIES) food triggers may be safe for carefully preselected children with food allergies according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, in Washington, DC this month.

Key Points: 
  • MILWAUKEE, Feb. 13, 2024 /PRNewswire-PRWeb/ -- Home reintroduction of pediatric food protein-Induced enterocolitis syndrome (FPIES) food triggers may be safe for carefully preselected children with food allergies according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, in Washington, DC this month.
  • Continued research in this area will enable allergists to make shared decisions with patient families, identifying suitable candidates among children with FPIES for gradual home reintroduction of triggers at appropriate ages.
  • With a median age of 23.5 months, 28 patients attempted reintroduction of FPIES food triggers with 71.5% of reintroduction at home and 28.5% in a medical facility as a formal food challenge.
  • With home reintroduction considered safe for carefully preselected children, children have more treatment options and may have better outcomes and improved quality of life, the research shows.

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Retrieved on: 
Monday, February 12, 2024
SAN, Connect, Investment, Marketing, Amgen, Atopic dermatitis, Johnson & Johnson, Asthma, Bristol Myers Squibb, Eos, CNTB, University, Therapy, Business, Patient, KPCB, GSK plc, Chemical engineering, Kleiner Perkins, Pharmaceutical industry

James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company.

Key Points: 
  • James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company.
  • “We are thrilled to welcome James to Connect’s Board of Directors,” said Wubin (Bill) Pan, Ph.D., M.B.A., Co-Founder, President, and Chairman of the Board of Connect Biopharma.
  • “His breadth of biotech and investment experience, coupled with his passion for innovative and transformative life science companies will provide our Board with a unique perspective.
  • Additionally, Mr. Huang serves as a director on the board of directors of a number of companies, including Kindstar Global, TacTiva Therapeutics, TriArm Therapeutics, Chime Biologics, Eos, GT Aperion, Domain, Asia Pacific Medical and XWPharma.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
Monday, February 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.